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An accurate assessment of iron status in dialysis patients is
important because both anemia and overtreatment with
erythropoiesis-stimulating agents are associated with poor
clinical outcomes. We have previously shown that both
analytical and intra-individual (biological) variability in serum
ferritin limits its utility as a proxy for iron stores in patients in
this setting. As hepcidin is a direct regulator of iron status, its
measurement might be useful for monitoring patients with
iron dysregulation. We assessed short-term intra-individual
variation of serum hepcidin in 28 patients with stable
chronic kidney disease on hemodialysis. The intra-individual
variability for serum hepcidin ranged from 9–79% during
an initial 2-week to 12–85% over a 6-week period. The
concentration of serum hepcidin was significantly correlated
with serum C-reactive protein levels over the 6-week study
period. Hence, significant intra-individual variability of
hepcidin is likely dependent on short-term fluctuations in the
inflammatory state. Thus, our results suggest that short-term
measurement of serum hepcidin should not be used to guide
clinical decisions regarding management of iron status
in chronic hemodialysis patients.
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Patients on chronic hemodialysis should undergo laboratory
assessment of their hematological and iron status at least
every 3 months according to the 2006 National Kidney
Foundation KDOQI (Kidney Disease Outcomes Quality
Initiative) Guidelines and Clinical Practice Recommenda-
tions.1 At present, this assessment includes measurement of
serum ferritin and transferrin saturation. An accurate
assessment of iron status is important because both anemia2
and overtreatment with erythropoiesis-stimulating agents3–5
are associated with poor clinical outcomes.
We have previously shown that both analytical and intra-
individual (biological) variability in serum ferritin limits its
utility as a proxy for iron stores in patients with chronic
kidney disease (CKD) on hemodialysis.6 Ferritin is an acute-
phase reactant that may not correlate with iron status in
chronic disease states, such as CKD.7 This has led to a search
for better markers of iron status in CKD patients on
hemodialysis, with serum hepcidin emerging as a promising
candidate.8,9 Hepcidin was originally described as an
antimicrobial peptide produced by the liver but its main
biological role seems to be iron homeostasis. It suppresses
iron absorption from the intestine and stimulates iron
retention in cells expressing ferroportin, notably macro-
phages and hepatocytes.10
Owing to its role as a direct regulator of iron status,
measurement of serum hepcidin is conceptually attractive in
patients with iron dysregulation. Ganz et al.11 recently
validated an immunoassay for serum hepcidin-25 by
establishing reference intervals in healthy volunteers, deter-
mining its analytical performance, and demonstrating that
serum hepcidin was low in patients with iron deficiency
anemia and high in classical hereditary hemochromatosis.
The primary objective of this study was to use this new assay
to assess intra-individual variability in serum hepcidin
concentrations in stable CKD patients on chronic hemodia-
lysis over a total of 6 weeks and compare it with that of serum
ferritin. A secondary objective was to compare the variability
in serum C-reactive protein (CRP) with that of serum
hepcidin and ferritin to estimate the degree to which
inflammatory status may influence the concentration of
these two analytes.
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RESULTS
Intra-individual variability of serum hepcidin and
serum ferritin
The characteristics and baseline laboratory results of the 28
patients are summarized in Table 1. Both gender and race
distributions are consistent with patient demographics in our
urban hemodialysis centers. The median intra-individual
coefficient of variability (CVI) of serum hepcidin over 2
weeks (n¼ 4 samples per subject) was 19.0% (interquartile
range (IQR): 13.0, 25.2%) (Table 2). For the 6-week period
(n¼ 8 samples per subject), the median CVI for serum
hepcidin was 22.9% (IQR: 18.0, 39.7%). In comparison, the
median CVI of serum ferritin for these 28 patients over the
2-week period was 8.6% (IQR: 5.2, 13.7%). For the 6-week
period, the median CVI of serum ferritin was 11.5% (IQR:
7.3, 17.8%). CVIs of serum hepcidin and ferritin were
uncorrelated over either the 2- or the 6-week period, and the
serum hepcidin CVIs for the three groups of patients
stratified by initial serum ferritin were not different over
6 weeks (P¼ 0.32, analysis of variance).
There was a wide variation in the correlation of these
markers within subjects (Figure 1). There was a statistically
significant (Po0.05) within-subject correlation between
serum hepcidin and ferritin in 5 of the 28 patients. Of these,
four exhibited a positive correlation and one exhibited a
negative correlation (Figures 1 and 2a). All others showed no
statistically significant correlation between ferritin and
hepcidin concentrations with several examples shown in
Figure 2b. Within-individual correlation of hepcidin with
CRP and ferritin with CRP was also widely variable with
correlations reaching significance in only four and six
subjects, respectively (Figure 1). Comparing all ferritin–hep-
Table 1 | Baseline and end-of-study demographic and
biochemical characteristics of patient groups (mean (s.d.))
Parameter Value (n=28)
Age (years) 57.5 (11.7)
Men (n (%)) 10 (36)
African American (n (%)) 24 (86)
Hemoglobin (g/100ml) 11.6 (1.0)
Poststudy hemoglobin (g/100ml) 11.5 (1.3)
Mean prestudy ferritin (ng/ml)a 671 (273)
Mean end-study ferritin (ng/ml)b 582 (257)
Mean epoetin dose per week (IU) 19,667 (22,411)
Mean i.v. iron dose (mg per week) 31 (24)
Ferrlecit/venofer/none 8/14/6
Abbreviation: i.v., intravenous.
aPrestudy ferritin used to recruit patients, analyzed by Spectra Laboratories
(Fremont, CA, USA) on the Siemens (Bayer) Centaur (Siemens, Berlin, Germany).
bSerum ferritin concentration of the final patient sample, analyzed on the Siemens
(Bayer) Centaur.
Table 2 | Individual 2-week (n=4, left) and 6-week (n=8, right) coefficients of variation (CVI, %)
2 Weeks (n=4) CVI (n=28) 6 Weeks (n=8) CVI (n=28)
Hepcidin Hepcidin
Range 8.5–79.1 Range 11.6–85.4
Median 19.0 Median 22.9
IQR 13.0–25.2 IQR 18.2–39.7
Arithmetic mean (s.d.) 23.6 (16.1) Arithmetic mean (s.d.) 29.2 (16.7)
Ferritin Ferritin
Range 2.2–62.0 Range 4.8–51.6
Median 8.6 Median 11.5
IQR 5.2–13.7 IQR 7.3–17.8
Arithmetic mean (s.d.) 12.0 (12.0) Arithmetic mean (s.d.) 13.8 (9.8)
CRP CRP
Range 12.3–137.2 Range 9.9–160.3
Median 45.5 Median 53.0
IQR 23.3–72.0 IQR 39.2–81.9
Arithmetic mean (s.d.) 12.0 (37.2) Arithmetic mean (s.d.) 64.4 (40.1)
Abbreviations: CRP, C-reactive protein; IQR, interquartile range.
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Figure 1 |Distribution of within-individual correlation
(r-values) between hepcidin, ferritin, and CRP over 6 weeks.
Circles: intra-individual correlations (r-values, Y axis) between
hepcidin–ferritin, hepcidin–CRP, and ferritin–CRP over 6 weeks.
Open circles: P40.05; solid circles: Pp0.05. CRP, C-reactive
protein; fer, ferritin; hep, hepcidin.
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cidin sample pairs as a group rather than within individuals,
serum ferritin and hepcidin were correlated (r¼ 0.57,
Po0.01, Figure 3a). Hepcidin and CRP were correlated
(Figure 3b), whereas ferritin and CRP were not significantly
correlated (Figure 3c).
Among other measures related to iron status, the average
epoetin dose per week was negatively correlated with
transferrin saturation at mid-study (3 weeks; r¼0.46,
P¼ 0.01) and negatively correlated with the average iron dose
per week (r¼0.42, P¼ 0.03). However, the average epoetin
dose was not correlated with the change in serum hepcidin
over the course of the study (Figure 3d). In addition, average
epoetin dose did not correlate with baseline hepcidin or
average hepcidin over 6 weeks. Mean serum hepcidin was not
significantly correlated with either mean transferrin satura-
tion (r¼ 0.21, P¼ 0.28) or mean weekly iron dose (r¼ 0.08,
P¼ 0.70).
Correlation of serum hepcidin, ferritin, and CRP
intra-individual variability
CVIs for serum hepcidin over 2 and 6 weeks had modest
positive correlations with CVIs for CRP over 6 weeks
(r¼ 0.42 and r¼ 0.43; P¼ 0.03 and P¼ 0.02, respectively).
Serum ferritin over 2 and 6 weeks was not significantly
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Figure 2 | Individual trends in hepcidin and ferritin over 6 weeks. Open circles: hepcidin values. Closed circles: ferritin values. Left
number: patient number. Y axis: change (%) over baseline. X axis: study week number, with half weeks over the first 2 weeks. (a) Patients
with a significant intra-individual correlation in variation between hepcidin and ferritin. Patient 14 has a negative correlation; the others
exhibit positive correlation. (b) Randomly selected patients with uncorrelated variation in hepcidin and ferritin.
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Figure 3 |Correlations between pairs of values across the entire study population. (a–d) Solid line; linear regression. Dashed lines;
95% confidence envelope for regression. (a–c) As labeled. (d) Average epoetin dose per week (units of epoetin alfa) vs the difference in the
first and final measurements of serum hepcidin over 6 weeks.
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correlated with CVIs for CRP (r¼ 0.22 and r¼ 0.23; P¼ 0.25
and P¼ 0.25, respectively). Similarly, CVIs for serum
hepcidin and serum ferritin over 2 or 6 weeks were not
significantly correlated with CVIs for CRP over 2 weeks.
DISCUSSION
This study demonstrates large intra-individual variability in
serum hepcidin over 2- and 6-week periods that appears to
be similar to that observed for serum ferritin, which is a more
commonly used, but imperfect, indicator of iron status in
CKD patients on hemodialysis. As we selected patients for
stable clinical status and consistent iron and epoetin dosing,6
the intra-individual variability among all dialysis patients is
likely to be even higher for both serum hepcidin and ferritin.
Clinically significant changes in laboratory measurements
can be defined by the reference change value or critical
difference,12 which encompasses both intra-individual
variation (CVI) and analytical variation (CVA). For 95%
confidence that a physiological change has occurred, the
reference change value is calculated as 2.77 (CVA2þCVI2)0.5.
Assuming a CVA of 7%
11 and the biological variability (CVI)
listed in Table 2, the critical difference is 56 and 66% over the
2- and 6-week periods, respectively, using the median CVIs
for serum hepcidin. Considering the mean serum hepcidin of
553 ng/ml (similar to the median serum hepcidin 652 ng/ml
as observed by Zaritsky et al.13 in a pediatric population on
hemodialysis) a physiological change in our study population
would be defined as ±365 ng/ml over 6 weeks. As we have
previously described for ferritin,6 this likely limits the clinical
utility of hepcidin as an indicator of iron stores and of short-
term changes in iron status in CKD patients on hemodialysis.
Ashby et al.14 showed a decrease of B20 ng/ml in serum
hepcidin in six healthy subjects administered recombinant
human erythropoietin. There may be several reasons why we
did not see a correlation between epoetin dose and serum
hepcidin. The many differences in physiology between
healthy subjects and our patient population, leading to the
high intra-individual variability seen herein, may mask a
statistically significant correlation if the magnitude of the
epoetin effect is on the order of that observed by Ashby et al.
Alternately, it may be that iron metabolism is sufficiently
dysregulated in patients on chronic hemodialysis that there is
no correlation; a large interventional trial would be better
suited to explore this possibility.
Some of the larger intra-individual variations in serum
hepcidin relative to serum ferritin observed in this study may
be due to a larger dependence of serum hepcidin on short-
term changes in the inflammatory state, as suggested by the
modest correlation between serum hepcidin and CRP and
the lack of any correlation between serum ferritin and CRP.
Ganz et al., using the assay in this study, found a positive
correlation between serum hepcidin and ferritin in healthy
subjects, as well as a correlation between serum hepcidin and
elevated CRP.11 The fact that serum hepcidin is closely tied to
systemic inflammation may limit its use as a proxy for iron
status in CKD patients, who often exhibit chronic inflamma-
tion. The large intra-individual variability in CRP observed in
this population (CVI¼ 45.5% over 2 weeks and CVI¼ 53%
over 6 weeks) is very similar to that measured in a similar-
sized population of healthy subjects (26 normal subjects,
CVI¼ 42.2%15), suggesting that we have successfully selected
a similarly stable population of patients. We expect that in a
population not selected for clinical stability and in which
blood draws are performed with less attention to the timing
of iron administration, both the CVIs for serum hepcidin and
ferritin might be even greater.16–18 It is clear that serum
hepcidin reflects both iron status and inflammation, making
it difficult to interpret strictly in terms of iron status.
Most of the hepcidin assays that have been produced to
date are not applicable to an anuric population as they assay
urine hepcidin.19,20 Other assays are semi-quantitative21 or
require complicated procedures unlikely to be practical
in common clinical laboratory settings.22 However, among
assays for mature hepcidin, there is agreement between
methods of measurement of urine and serum hepcidin,23,24
and most assays show analytical CVs similar to the assay used
in this study.25–27,11 Furthermore, different assays show a
similar association with CRP28,29 that was recently duplicated
by Zaritsky et al.30 in patients on hemodialysis despite
withholding parenteral iron for 1 week before hepcidin
measurement. Given these findings, we do not expect that the
lack of standardization among mature hepcidin assays to
substantially affect our findings. A potential limitation might
be that the assay used in this study detects forms of hepcidin
other than hepcidin-25, which may be both physiologically
inactive and present in high concentrations in patients on
hemodialysis. Although this potential effect is uncharacter-
ized in this case, Ashby et al.14 reported that a polyclonal
antibody produced identically to that used in this assay11 had
o10% cross-reactivity with species of hepcidin other
than hepcidin-25, similar to that seen in healthy controls.
In conclusion, we have shown using a validated serum
hepcidin assay that serum hepcidin exhibits both a high CVI
and also correlates with CRP in stable patients with CKD on
hemodialysis. These findings indicate that mature serum
hepcidin may not provide an advantage over ferritin as a
useful indicator of iron status in this patient population.
MATERIALS AND METHODS
Study design
This study was approved by the Human Studies Committee at the
Washington University as a subset of a previous study.6 Additional
informed consent to use previously collected patient specimens was
obtained. The study consisted of determination of intra-individual
variability in serum hepcidin and serum CRP concentration over
2 and 6 weeks in stable chronic hemodialysis patients. Ferritin values
were obtained in samples after one freeze-thaw cycle in the previous
study.6 Overall, 9–10 patients from each of the three study groups
from the previous study were selected (high, intermediate, and low
initial serum ferritin groups) for further serum hepcidin analysis.
Samples underwent a total of two freeze-thaw cycles before hepcidin
measurement. Serum hepcidin has previously been shown to be
stable through at least 6 months of storage and one freeze-thaw
772 Kidney International (2010) 78, 769–773
or ig ina l a r t i c l e BA Ford et al.: Intra-individual variability in serum hepcidin
cycle in the assay used in this study,11 and is stable through two
freeze-thaw cycles (T Ganz, personal communication, unpublished
data) in this assay and at least four freeze-thaw cycles in a mass
spectroscopic method.23
Samples were obtained twice a week for 2 weeks and then once a
week for the next 4 weeks for a total of eight samples from each
patient. Patients were 418 years of age, not pregnant, and on
chronic hemodialysis three times per week, had missed no more
than one hemodialysis session in the last 4 weeks, and had a baseline
hemoglobin410 g/100 ml. Patients were receiving either no iron or
maintenance iron intravenously (defined as p125 mg per week of
ferric gluconate or iron sucrose) for the previous 4 weeks. None had
a change in iron dosing over the course of the study. No patients
were receiving oral iron. All patients were receiving epoetin alfa
(Epogen; Amgen; Thousand Oaks, CA, USA).
One patient had a single ferritin concentration of 8710 ng/ml in
the fourth week that was confirmed three times and excluded from
data analysis as an outlier; no other values were identified as
outliers. Patient 11 did not have a sixth-week hepcidin sample, and
patient 16 did not have a final poststudy hemoglobin sample drawn
because of receipt of a kidney transplant; statistics were calculated
without these values.
Exclusion criteria were active bleeding in the previous 8 weeks,
transfusion within the last 12 weeks, any hematological disorder
other than anemia, cancer, Gaucher’s disease, acute or chronic
liver disease, HIV (human immunodeficiency virus)-positive status,
a history of autoimmune disease, antibiotics in the last month, or
enrollment in another study.
Overall, 10 patients had initial ferritin 200–500 ng/ml; 9 patients
had ferritin 500–800 ng/ml; and 9 had ferritin 800–1200 ng/ml.
Blood was obtained immediately before administration of intrave-
nous iron to minimize the contribution of intravenous iron to
short-term intra-individual variability in serum iron indices.
Samples were processed within 1 h of drawing and stored at
80 1C Serum hepcidin testing was performed on a fee for service
basis at Intrinsic Life Sciences (La Jolla, CA, USA), which uses the
assay described by Ganz et al.11 This assay is a competitive enzyme-
linked immunosorbent assay for hepcidin-25 that has a published
median analytical CV of 7%. All samples from any one patient were
performed in the same run.
Statistical analysis
Short-term intra-individual variability in serum hepcidin and
ferritin was summarized as CVI and IQRs. Day-to-day (over 2
weeks) and week-to-week (over 6 weeks) CVIs were calculated
for each volunteer, as well as the mean, median, and range of CVIs
for serum hepcidin and ferritin. Correlation coefficients were used
to assess associations between variables, and outliers were excluded
according to the method of Hadi.31 A P-valueo0.05 was considered
significant. All calculations were performed using SYSTAT
12 (Systat, Chicago, IL, USA).
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